Nicole Mather retweeted
And for anthropic's team and others, come and discover with us (and if you want to do AI in biology in beautiful Heidelberg/Cambridge/Barcelona/Grenoble/Hamburg/Rome - check out @embl - we are hiring PhD students now - and will be hiring group leaders next year)
Nicole Mather retweeted
We have today appointed my brilliant colleague, Lord Vallance, to chair the PM’s AI Taskforce.
Patrick and I worked closely together before. We will now do so again, with the urgency and importance of the Vaccines Taskforce, applied to the central question of artificial intelligence.
gov.uk/government/news/ai-to…
Nicole Mather retweeted
New AI paper from us this week. When my student first showed me his initial findings, I really didn’t know what to make of them. I felt that this was an interesting but curious loophole phenomenon that would shortly be closed. I was very wrong.
arxiv.org/abs/2603.21687
#Bluesky nicolemather.bsky.social is moving.. see y’all there
1
148
Nicole Mather retweeted
We are recruiting up to 5 Pandemic Sciences Research Fellows at @UniofOxford. Posts are for recent graduates to carry out independent research on topics in one or more of the following areas: AI & Epi, Genomics, Climate & Infectious diseases, Global health digital data science ↓
Nicole Mather retweeted
So @JeremyFarrar asked for an "explainer thread" on Noble Prizes in Chemistry around AlphaFold and Protein design, so here goes.
Nicole Mather retweeted
Brilliant! Just brilliant! Congratulations to David, @demishassabis and John. So well deserved!
BREAKING NEWS
The Royal Swedish Academy of Sciences has decided to award the 2024 #NobelPrize in Chemistry with one half to David Baker “for computational protein design” and the other half jointly to Demis Hassabis and John M. Jumper “for protein structure prediction.”
Nicole Mather retweeted
Today, we can announce a new industry-government partnership with up to £400 million of investment to support faster patient access to cutting-edge treatments, strengthen clinical trials, and improve UK medicine manufacturing.
Find out more: abpi.org.uk/media/news/2024/… @DHSCgovuk @UK_Life_Science @SciTechgovuk
Nicole Mather retweeted
Great #patient #advocacy opportunity here (not that I'm biased)! Please share. Applications open now: see link for further details.
#RareDisease #CancerGenomics #GenOMICC #Genomes100k #GenerationStudy
@GenePeopleUK @GeneticAll_UK @Cancer52org @Unique_charity
The Participant Panel at Genomics England is recruiting for a new Chair. Applications close on 30 September.
Apply here: ow.ly/7oPr50ST0Vy
Nicole Mather retweeted
Interim Innovate UK Executive Chair appointed ukri.org/news/interim-innova…
Nicole Mather retweeted
Delighted to be appointed Chair of Warwick Innovation at one of the most exciting times in history for science, technology and innovation.
Honoured to build on the huge achievements of Lord Bhattacharyya & colleagues’ work at @wmg, @uniofwarwick and beyond.
#IndustrialStrategy
We've appointed @GregClarkMP as the first Executive Chair of Warwick Innovation District.
He will take up the post in October and will be the driving force behind the establishment of the new organisation.
Find out more about Greg's new role ⬇️
warwick.ac.uk/newsandevents/…
Nicole Mather retweeted
CRISPR was just the start
Two papers in @Nature present a new genome editing technique that enables the insertion, inversion and deletion of long DNA sequences at user-specified genome positions. The approach may provide an easier method of genome editing.
go.nature.com/3RGkI8M
go.nature.com/3RHBvIs
Investing in health research capacity & skills will be critical for driving future innovations & partnerships, making the most of our health data, assets enabling improvements for patients, thus UK productivity & growth @profadmorris @emma_k_lowe @NIHRresearch @UK_Life_Science
🚨 New in @TheLancet: Academy President Professor Andrew Morris PMedSci calls on Government to prioritise NHS research as a catalyst for better health and economic growth.
He also outlines 5 key areas to strengthen UK health research. Read the article 👇
thelancet.com/journals/lance…
3
378
Nicole Mather retweeted
Big statement alert:
This is a LANDMARK in the history of clinical gene editing. This means we can dose to effect. This means we can sequentially edit targets. This means we can reverse certain edits.
Cue "A whole new wooorld..."
Intellia announces new data from patients redosed with an investigational in vivo #CRISPR-based therapy at the Peripheral Nerve Society (@PNSociety1) Annual Meeting. Full details here: ir.intelliatx.com/news-relea…
#geneeediting #PNS2024
Nicole Mather retweeted
1/3 🧵
Ahead of the UK #GeneralElection2024, we are co-hosting a free science, innovation and technology hustings.
Hear directly from political party representatives, & ask them your questions on science policy.
Watch live from 6:30pm, Wednesday 19 June youtube.com/live/ok2wzr-ZQbU…
Nicole Mather retweeted
Moderna can make 34 custom mRNAs on demand - GMP - IN TWO WEEKS to treat a person with cancer.
The same can be true for CRISPR Cures for a devastatingly ill infant who needs a custom gRNA to save their life.
Yes it can.
Watch this space.
Great to see real NHS productivity improvements for patients recognised by #HSJPartnershipAwards @nhsuhcw @IBM
This Post is from an account that no longer exists. Learn more
2
314
Nicole Mather retweeted
Inspiring talk from Pearse Keane driving home that successful deployment of AI will require coordinated networks of innovation and robust business models @pearsekeane @HDR_UK
Nicole Mather retweeted
There’s one day left to apply for @TheEconomist science and tech writing internship. If you want to work with us for three months over the summer, the details are here: economist.com/casement2024



























